Low Density Non-Calcified Plaque Volume

Not all artery plaque is equal. Some plaque is hard, stable, and calcified like a scab that has hardened over years. Other plaque is soft, fatty, and prone to rupturing, which is what actually causes most heart attacks. This measurement tells you how much of the dangerous kind you are carrying in your coronary arteries right now.

In a study of 1,769 adults with stable chest pain, people whose low-attenuation plaque made up more than 4% of their vessel volume were nearly five times more likely to have a heart attack over the following years. That signal was stronger than the standard cholesterol score, the calcium score, or how narrow the arteries looked.

What This Measurement Actually Captures

LD-NCP (low-density non-calcified plaque), also called LAP (low-attenuation plaque), is the softest, most lipid-rich subset of artery plaque visible on a coronary CT angiogram. The CT scanner measures how strongly each speck of tissue absorbs X-rays, reported in a unit called Hounsfield units (HU). Plaque below roughly 30 to 45 HU on this scale tends to be packed with fat, inflammatory cells, and dead tissue, the recipe for a plaque that can crack open and form a clot. A 30 HU cutoff has been the most widely used threshold in prognostic studies, while 45 HU has shown the strongest correlation with lipid-rich plaque on invasive imaging.

When compared head-to-head with intravascular ultrasound, the invasive gold standard for looking inside arteries, a 45-HU threshold gave the strongest correlation with lipid-rich plaque size, with a diagnostic accuracy score of 0.878 (where 1.0 would be perfect). The volume of this soft plaque, measured in cubic millimeters or as a percentage of vessel wall, is what this test reports.

Heart Attack Risk

The single most important finding about this measurement is its ability to predict who will have a heart attack. In the SCOT-HEART analysis of 1,769 adults, low-attenuation plaque burden was the strongest predictor of myocardial infarction over five years, beating cardiovascular risk scores, calcium scoring, and the degree of artery narrowing. People above the 4% threshold had roughly five times the risk of the people below it.

A separate study of 1,697 patients found that combining a low-attenuation plaque burden above 4% with elevated inflammation in the fat surrounding the arteries pushed the hazard ratio for heart attack to roughly 11.7. In other words, when soft plaque and vessel inflammation appear together, the combined risk is about twelve times higher than baseline.

Cardiac Death and Major Events

In a nested case-control analysis drawn from 2,748 people followed long-term (32 cardiac deaths matched to 32 controls), low-density non-calcified plaque volume above 10.6 cubic millimeters was independently linked to roughly twice the risk of cardiac death (hazard ratio 2.26). This held up even after adjusting for how many heart artery segments showed disease.

Across 1,469 patients followed for several years, low-attenuation plaque under 60 HU and the napkin-ring sign (a specific plaque pattern) were the two strongest predictors of major adverse cardiac events. People with low-attenuation plaque had roughly five times the risk of those without it (hazard ratio 4.96).

Blocked Blood Flow and Active Ischemia

This marker also predicts whether a plaque is actively choking off blood flow. In 254 patients undergoing invasive testing, low-density non-calcified plaque volume above 30 cubic millimeters predicted flow-limiting blockages independently of how narrow the artery appeared. Adding this measurement to standard stenosis assessment raised diagnostic accuracy from 0.71 to 0.79.

Why It Beats Cholesterol and Calcium Scores

A standard lipid panel tells you what is in your blood. A calcium score tells you how much hardened, stable plaque you have accumulated. Neither measures the soft, fatty plaque that actually ruptures and causes heart attacks. In the SCOT-HEART analysis, low-attenuation plaque burden correlated only weakly with traditional cardiovascular risk scores and added prognostic information beyond calcium scoring.

This explains a confusing pattern many people experience: a normal cholesterol panel and a low calcium score, yet a heart attack anyway. The standard tests can miss a high burden of soft plaque hiding behind clean-looking labs. Among 23,143 symptomatic adults, the absence of both calcified and non-calcified plaque was tied to low cardiovascular risk even with markedly elevated LDL. The plaque itself, not the bloodwork alone, drives the risk.

Conditions That Drive Soft Plaque Higher

Soft plaque burden is shaped by both classic risk factors and unexpected sources of inflammation. In 376 adults without known coronary disease, a coronary calcium score above 218 and an epicardial fat volume above 125 mL were the two strongest independent predictors of being in the highest quartile of low-attenuation plaque.

In 172 patients with lupus, soft plaque burden was significantly higher than in matched controls, with the gap widest in middle-aged women and those on prednisone doses above 10 mg per day. People with type 2 diabetes show accelerated soft plaque growth, and lifelong endurance athletes, despite excellent fitness, can carry more non-calcified plaque in proximal arteries than expected. The common thread is chronic vessel-wall inflammation, not just elevated cholesterol.

Why One Reading Is Not Enough

Plaque biology changes slowly, but it does change, especially with treatment. Serial CT angiograms can show whether your soft plaque is growing, stable, or regressing. This trajectory matters more than any single snapshot, because it tells you whether your current prevention strategy is working.

Reproducibility is high for total and non-calcified plaque volumes between scans, and historically moderate for the low-density subset specifically (correlation around 0.74 to 0.77). More recent work using AI-enabled software with side-by-side assessment and scan-specific thresholds has shown excellent scan-rescan agreement (intraclass correlation 0.96 or higher) for all plaque subcomponents, including the low-density subset, so the choice of analysis software and workflow meaningfully affects how much measurement noise to expect. Trends become most meaningful when read over years, not months. A reasonable cadence is a baseline scan, a follow-up at 2 to 3 years if you are making major lifestyle or medication changes, and longer intervals once your numbers are stable. Image quality, scan protocol, and the analysis software all influence reproducibility, so using the same lab and same scanner type for serial measurements is ideal.

When Results Can Be Misleading

Because LD-NCP is defined by a fixed Hounsfield unit threshold, the scanner settings themselves can shift the number without changing your underlying biology. Key sources of variation:

• Tube voltage: lower kV settings, especially 70 kV, increase how bright the contrast-filled artery appears and can artificially shift apparent plaque composition toward more calcified and less low-attenuation tissue.
• Photon-counting CT settings: changing the energy level used to reconstruct the image significantly alters estimated low-attenuation plaque volume, because the volume is defined by a fixed cutoff that the energy setting can cross.
• Image quality and motion: heart rate variation, breath holding, and contrast timing affect how clearly the plaque borders are seen, especially for the small low-density subset.
• Analysis software: different AI tools and reconstruction algorithms can produce different volumes from the same scan.

For these reasons, serial scans are most meaningful when the same scanner, protocol, and analysis software are used each time.

What to Do With an Elevated Result

A high low-attenuation plaque burden is not a diagnosis, it is a roadmap. The first step is to look at the full picture: your ApoB, Lp(a), inflammatory markers like hs-CRP, fasting insulin, and the pericoronary fat attenuation around your arteries on the same scan. Inflammation in the surrounding fat, when paired with high soft plaque, multiplies the risk and points toward more aggressive lipid lowering and inflammation control.

If you carry a high soft plaque burden, working with a preventive cardiologist or lipidologist is reasonable, especially if your standard labs look unremarkable. In a single-arm, open-label study of 47 patients, 18 months of evolocumab (a PCSK9 inhibitor) reduced low-attenuation plaque volume from 37.1 to 20.4 microliters while increasing calcified plaque, shifting the overall plaque toward a more stable phenotype. In 857 patients followed across multiple scans, statin use was associated with measurable decreases in low-attenuation plaque and a shift toward dense, stable calcium. Your treatment options exist; the test just tells you whether they are warranted.